Finance

Lists
Why is GLAXO down 2,29%?
Dive Deeper
GLAXO:NSE
GlaxoSmithKline Pharmaceuticals Ltd
2 626,00 INR
-2,29%
(-61,60) 1D
18-ноя., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for GLAXO...
Open
2 698,80 INR
High
2 699,00 INR
Low
2 620,20 INR
Mkt. cap
444,67 млд
Avg. vol.
89,40 миң
Volume
87,84 миң
Dividend
2,17%
Quarterly dividend
14,25 INR
Ex-dividend date
2026-ж., 29-май
P/E ratio
38,80
52-wk high
3 120,70 INR
52-wk low
2 088,10 INR
EPS
67,68 INR
Shares outstanding
169,41 млн
No. of employees
3 миң
Open
2 698,80 INR
High
2 699,00 INR
Low
2 620,20 INR
Mkt. cap
444,67 млд
Avg. vol.
89,40 миң
Volume
87,84 миң
Dividend
2,17%
Quarterly dividend
14,25 INR
Ex-dividend date
2026-ж., 29-май
P/E ratio
38,80
52-wk high
3 120,70 INR
52-wk low
2 088,10 INR
EPS
67,68 INR
Shares outstanding
169,41 млн
No. of employees
3 миң
News stories
From web sources and news partners
Profile
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, and others. Wikipedia
About GlaxoSmithKline Pharmaceuticals Ltd
CEO-
Employees3,1 миң
Founded1924-ж., 13-ноя.
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Last report
2026-ж., 3-ноя.
Fiscal period
Q2 2027
19,83 INR / 16,50 INR
+20,18%beat
Revenue / Est. (INR)
11,84 млд / 10,79 млд
+9,66%beat
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
10,41 млд
9,95 млд
9,38 млд
11,84 млд
Cost of goods sold
3,64 млд
3,69 млд
3,28 млд
4,44 млд
Cost of revenue
3,64 млд
3,69 млд
3,28 млд
4,44 млд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,52 млд
2,95 млд
1,59 млд
1,70 млд
Operating expense
3,26 млд
2,84 млд
3,31 млд
3,52 млд
Total operating expenses
6,90 млд
6,53 млд
6,59 млд
7,97 млд
Operating income
3,51 млд
3,43 млд
2,80 млд
3,87 млд
Other non operating income
321,20 млн
-1,09 млд
437,60 млн
727,80 млн
EBT including unusual items
4,00 млд
3,73 млд
3,22 млд
4,59 млд
EBT excluding unusual items
3,82 млд
2,94 млд
3,22 млд
4,59 млд
Income tax expense
1,04 млд
952,41 млн
852,70 млн
1,23 млд
Effective tax rate
26,08%
25,53%
26,44%
26,88%
Other operating expenses
1,54 млд
-236,82 млн
1,56 млд
1,67 млд
Net income
2,96 млд
2,78 млд
2,37 млд
3,36 млд
Net profit margin
28,39%
27,92%
25,27%
28,38%
Earnings per share
-
-
14,00
19,83
Interest and investment income
-
657,30 млн
-
-
Interest expense
-11,90 млн
-6,12 млн
-9,70 млн
-4,90 млн
Net interest expenses
-11,90 млн
651,18 млн
-9,70 млн
-4,90 млн
Depreciation and amortization charges
203,20 млн
131,74 млн
158,40 млн
150,20 млн
EBITDA
3,61 млд
3,52 млд
2,89 млд
4,02 млд
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google колдонмолору